TTY Biopharm Company Limited (TPEX:4105)
Taiwan · Delayed Price · Currency is TWD 76.00
+0.30 (0.40%)
Jul 30, 2026, 9:50 AM CST
TTY Biopharm Company Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,515 | 6,453 | 5,894 | 5,506 | 5,062 | 4,536 | |
Revenue Growth | 7.16% | 9.49% | 7.05% | 8.77% | 11.60% | 7.43% |
Cost of Revenue | 2,766 | 2,732 | 2,479 | 2,218 | 2,040 | 1,768 |
Gross Profit | 3,748 | 3,721 | 3,415 | 3,287 | 3,021 | 2,768 |
Selling, General & Admin | 1,780 | 1,821 | 1,750 | 1,601 | 1,436 | 1,325 |
Research & Development | 192.53 | 194.35 | 271.39 | 310.44 | 353.44 | 287.6 |
Other Operating Expenses | -5.06 | -0.03 | -1.44 | 4.95 | 0.38 | 1.43 |
Operating Expenses | 1,967 | 2,017 | 2,021 | 1,915 | 1,794 | 1,627 |
Operating Income | 1,781 | 1,704 | 1,394 | 1,372 | 1,228 | 1,141 |
Interest Expense | -35.37 | -37.94 | -38.26 | -35.18 | -22.85 | -18.97 |
Interest & Investment Income | 78.01 | 81.63 | 92.29 | 86.66 | 37.55 | 12.67 |
Earnings From Equity Investments | 178.38 | 164.87 | 400.05 | 131.34 | 116.38 | 135.18 |
Currency Exchange Gain (Loss) | -9.57 | -12.25 | 24.97 | 0.77 | 23.81 | 1.12 |
Other Non Operating Income (Expenses) | 210.54 | 243.95 | 20.53 | 17.29 | 29.5 | -178.39 |
EBT Excluding Unusual Items | 2,203 | 2,144 | 1,893 | 1,573 | 1,412 | 1,092 |
Gain (Loss) on Sale of Investments | - | 0.95 | - | -35.74 | - | - |
Gain (Loss) on Sale of Assets | -1.89 | -1.8 | -0.95 | -1.93 | -3.28 | -0.74 |
Asset Writedown | -18.18 | -18.18 | -6.8 | -116.18 | -0.73 | -4.15 |
Pretax Income | 2,183 | 2,125 | 1,886 | 1,419 | 1,408 | 1,087 |
Income Tax Expense | 473.42 | 470.47 | 366.33 | 300.86 | 305.25 | 264.81 |
Earnings From Continuing Operations | 1,710 | 1,655 | 1,519 | 1,119 | 1,103 | 822.57 |
Minority Interest in Earnings | -98.69 | -95.58 | -69.73 | 9.91 | -8.7 | 9.33 |
Net Income | 1,611 | 1,559 | 1,450 | 1,129 | 1,094 | 831.89 |
Net Income to Common | 1,611 | 1,559 | 1,450 | 1,129 | 1,094 | 831.89 |
Net Income Growth | 3.28% | 7.55% | 28.46% | 3.12% | 31.55% | -9.99% |
Shares Outstanding (Basic) | 249 | 249 | 249 | 249 | 249 | 249 |
Shares Outstanding (Diluted) | 249 | 249 | 249 | 249 | 249 | 249 |
Shares Change | 0.04% | 0.03% | 0.04% | 0.03% | -0.02% | -0.00% |
EPS (Basic) | 6.48 | 6.27 | 5.83 | 4.54 | 4.40 | 3.35 |
EPS (Diluted) | 6.47 | 6.26 | 5.82 | 4.53 | 4.40 | 3.34 |
EPS Growth | 3.36% | 7.56% | 28.48% | 2.96% | 31.74% | -9.97% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1,906 | 1,667 | 1,224 | 1,007 | 1,144 | 1,196 |
Free Cash Flow Per Share | 7.65 | 6.69 | 4.91 | 4.04 | 4.59 | 4.80 |
Dividend Per Share | 4.500 | 4.500 | 4.200 | 3.500 | 3.400 | 3.000 |
Dividend Growth | 7.14% | 7.14% | 20.00% | 2.94% | 13.33% | -25.00% |
Gross Margin | 57.54% | 57.66% | 57.94% | 59.70% | 59.69% | 61.03% |
Operating Margin | 27.34% | 26.41% | 23.65% | 24.93% | 24.26% | 25.15% |
Profit Margin | 24.73% | 24.16% | 24.60% | 20.50% | 21.62% | 18.34% |
Free Cash Flow Margin | 29.26% | 25.84% | 20.77% | 18.29% | 22.61% | 26.37% |
EBITDA | 1,975 | 1,892 | 1,588 | 1,566 | 1,409 | 1,303 |
EBITDA Margin | 30.32% | 29.32% | 26.95% | 28.43% | 27.83% | 28.74% |
D&A For EBITDA | 194.16 | 188.1 | 194.26 | 193.1 | 180.69 | 162.79 |
EBIT | 1,781 | 1,704 | 1,394 | 1,372 | 1,228 | 1,141 |
EBIT Margin | 27.34% | 26.41% | 23.65% | 24.93% | 24.26% | 25.15% |
Effective Tax Rate | 21.68% | 22.14% | 19.43% | 21.20% | 21.67% | 24.35% |